drugset
drugset / Trial / NCT02922426

An Insulin Sensitivity Study in Healthy Subjects

NCT02922426 ↗

Phase 1 Completed 60 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.

Timeline

Start
2016-09
Primary completion
2017-07-20
Completion
2017-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 3831 Unknown — Oral
Comparator Olanzapine Small molecule — Oral

Indications

No indication recorded.